Hasil Pencarian  ::  Simpan CSV :: Kembali

"Tujuan penelitian ini adalah membandingkan hasil pengobatan adenomiosis dengan reseksi dan pemberian inhibitor aromatase. Kasus adenomiosis dengan infertilitas dikumpulkan selama 3 tahuti (Januari 1999 sampai December 2001) yang ilikonfirmasi dengan USG transvaginal. Kasus dibagi 2 kelompuk, masing-masing kelompok I (dengan reseksi per laparotomi) dan kelompok 2 (mendapat inhibitor aromatase anastrozole). Keduanya dinilai tentang gejala klinik, angka kehamilan. dan angka perkainbuhan pascaoperasi. Selama 3 tahun telah ditangani 1619 kasus infertilitas, di antaranya 66 (4.07%) adenomiosis sebanyak 55 kasus dianalisis, terdiri alas 32 kasus kelompok I dan 23 kasus kelompok 2. Dan 32 kasus yang menjalani reseksi, hasil histopatologik menunjukkan 30 (93.75%) adenomiosis dan 2 (6.25%) mioma uteri. Dalatn kelompok 1, 3 kasus hamil, 2 melahirkan bay! hiditp, I kasus teraklnr dengan abortus pada kehamilan 6 minggu. Sebanyak 25 kasus (78.1%) tidak hamil,4 kasus (12.5%) mengalami perkainbuhan, dan pada 24 kasus (75.35%) gejala-gejala klinis hilang. Sementara itu, 23 kasus kelompok 2, sebanyak 2 (8.6%) hamil, masing-masing 1 lahir hidup dan I abortus. Sebanyak 14 kasus (59.1%) gejala klinik hilang. Selama pengobatan 3 bulan dengan inhibitor aromatase terjadi penunuum ukuran lesi antara 7.31 mm' dan 25.90 mm dengan Cl 95% (p < 0.001). Disimpulkan bahwa pengobatan dengan inhibitor aromatase tidak menyembuhkan lesi, hanya mengurangi ukuran lest adenomiosis. Sebaliknya reseksi dapat menghilangkan lesi walauptin perkainbuhan dapat terjadi (12.5%) sesudah I tahun pascaoperasi. (MedJ Indones 2006; 15:18-23).

---

The objective of this study was to observe the results of adenomyosis management with resection and administration of aromatase inhibitor. Cases ofademyosis in infertile women were collected for rhree years (January 1999 to December 2001) and the diagnoses were confirmed using transvaginal USG. Cases were grouped into two groups, i.e. group 1 (undergoing laparotomic resection) and group 2 (receiving treatment with aromatase inhibitor of anastrozole). Both groups were evaluated for changes in clinical symptoms, rate of successful pregnancy, and postoperative recurrency rate. During three years as many as 1619 infertility cases were managed, and among which 66 (4.07%) cases of adenomyosis were diagnosed with transvaginal USG. As many as 55 cases were analyzed, i.e., 32 cases underwent resection and 23 cases received aromatase inhibitor. Of 32 cases of surgical resection, the histopathologica! results showed 30 (93.75%) cases of adenomyosis and 2 (6.25%) cases of uterus myoma. In the group undergoing resection three cases (9.4%) were successfully pregnant, i.e., two cases had live birth, one case ended up with 6-week abortion. Moreover. 25 (78.1%) cases were not pregnant and 4 (12.5%) cases had recurrency, while 24 (75.35%) cases experienced disappearance of symptoms yet not pregnant. On the other hand, of 23 canes in the group receiving aromatase inhibitor 2 (8,6%) cases were able to be pregnant, one case had live birth and another case ended up with abortion, while 14 (59.1%) cases had disappearance of symptoms yet not pregnant. During three months of treatment with aromatase inhibitor, a reduction in the lesion size between 7.3! mm and 25.90 mm' were observed with Cl 95% (p < 0.001). In conclusion, treatment with aromatase inihibitor did not heal lesions, but only reduced the size of adenomyosis lesions. On the other hand, resection could heat lesions, yet recurrency of disease may occur (12.5%) after one postoperative year. (Med J Indones 2006; 15:18-23)."

"Latar belakang: Untuk menilai peningkatan imunitas selular terhadap biakan sel endometriosis dari sel LAK hasil perangsangan Sel Mononuklir Darah Tepi (SMDT) penderita endometriosis dengan IL-2. Metode: Studi ini merupakan penelitian kuasi-eksperimental pra dan pasca-perlakuan dengan menggunakan pembanding (kontrol). Dilakukan pemeriksaan fenotip CD3+ CD4+, CD3+ CD8+ dan CD56+ sel efektor dari SMDT endometriosis dan kontrol. Dilakukan pula uji sitotoksisititas SMDT penderita endometriosis dan kontrol terhadap lini-sel Daudi, K562, dan biakan sel endometriosis dengan menggunakan 51 Chromium pada teknik teraradioimun (radioimmunoassay, RIA). Hasil: Pada pemeriksaan fenotip SMDT dari 10 pasien endometriosis dan 6 pasien kontrol pada sebelum dan sesudah perangsangan dengan IL-2 ditemukan bahwa sebelum perangsangan dengan IL-2 ditemukan CD3+CD4+, CD56+ pada kelompok endometriosis lebih rendah daripada kelompok kontrol (p>0,05); fenotip CD3+ CD8+ pada kelompok endometriosis lebih tinggi daripada kelompok kontrol. Setelah perangsangan dengan IL-2 ditemukan CD3+CD8+, CD56+ dari SMDT kelompok endometriosis lebih tinggi daripada sebelum perangsangan dengan IL-2 dan ditemukan perbedaan yang bermakna (p < 0,05). Pada uji sitotoksisitas ditemukan peningkatan bermakna (p < 0,05) sitotoksisitas sel efektor baik pada SMDT endometriosis maupun SMDT kontrol terhadap sasaran (target) lini-sel Daudi dan K562 setelah perangsangan IL-2. Sitotoksisitas sel efektor baik pada SMDT endometriosis maupun SMDT kontrol terhadap sasaran biakan sel endometriosis setelah perangsangan IL-2 tampak meningkat. Kesimpulan: Sel LAK hasil perangsangan SDMT penderita endometriosis dengan IL-2 meningkatkan imunitas selular terhadap biakan sel endometriosis. (Med J Indones 2011; 20:87-93 ).

---

Background: To assess the increased cellular immunity of Peripheral Blood Mononuclear Cells (PBMC) derived LAK cells from endometriosis patients towards endometriosis cell cultures after stimulation with IL-2.

Methods: This study is a quasi-experimental study of pre and post treatment using controls. Phenotype evaluation of CD3+CD4+, CD3+CD8+ and CD56+ effector cells of PBMC from endometriosis patients and controls was performed. Cytotoxicity test of PBMC from endometriosis patients and control towards Daudi, K562 cell line and endometriosis cell cultures using 51Chromium release assay was also carried out.

Results: Phenotype evaluation of PBMC from endometriosis patients (n=10) and controls (n=6) were done prior to and after IL-2 stimulation. Before IL-2 stimulation, CD3+CD4+, CD56+ from endometriosis group (n=10) tend to be lower than control (n=6) whereas CD3+CD8 + were higher in endometriosis group than controls. After IL-2 stimulation, CD3+ CD8+, CD56+ of PBMC from endometriosis group were signifi cantly increased (p <0.05).Cytotoxicity test revealed a signifi cant increase (p <0.05) in both PBMCâ??s effector cells from endometriosis and control group towards target cells, Daudi, and K562 cell lines after IL-2 stimulation. PBMCâ??s effector cells cytotoxicity from both endometriosis and control towards target endometriosis cell cultures were also elevated after IL-2 stimulation.

Conclusion: LAK cells derived IL-2 stimulated PBMC from endometriosis patients increased cellular immunity towards endometriosis cell cultures. (Med J Indones 2011; 20:87-93 )."